Out Now! 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure

Heart Failure Beat: Guideline-Directed Medical Therapy in HF – Evidence vs. Practicality

Guideline-Directed Medical Therapy in HF – Evidence vs. Practicality

Tune into this episode to hear a discussion on GDMT and the gaps between the evidence and the practicality of implementation. They discuss the gap between trial-proven evidence-based heart failure therapies and implementation of these medications to our most vulnerable patients. Host Kevin Shah, MD, is joined by three HF providers across the career spectrum: Ted Berei, PharmD, Gregg C. Fonarow, MD, and Jonathan Davis, MD, MPH. 

Listen below and subscribe: Apple PodcastsGoogle Podcasts, SpotifyPodcast Home

Hosts

  • Kevin S. Shah MD, Assistant Professor of Medicine at the University Of Utah Heart Failure & Transplant Cardiology @KevinShahMD

Guests: 

  • Ted Berei, PharmD, Clinical Pharmacist, General Cardiology/Advanced Heart Failure - University of Wisconsin Hospitals and Clinics @chfpharmd

  • Jonathan Davis, MD, MPH, Associate Professor, UCSF, Director of the Heart Failure Program, San Francisco Health Network (SFHN) @JonathanDavisHF

  • Gregg C. Fonarow, MD, FHFSA, Eliot Corday Professor of Cardiovascular Medicine and Science at UCLA @gcfmd

 

Disclosures

  • Ted Berei, PharmD - Consultant: Cytokinetics
     
  • Jonathan Davis, MD, MPH - Consultant/Advisory Board: AstraZeneca 
     
  • Gregg C. Fonarow, MD, FHFSA - Consultant/Advisory Board: Abbott, Amgen, AstraZeneca, Bayer, Cytokinetics, Edwards, Janssen, Medtronic, Merck, and Novartis